Citation Report
List of articles citing

Proteasome inhibitors in multiple myeloma: 10 years later

DOI: 10.1182/blood-2012-04-403733
Blood, 2012, 120, 947-59.

#	Paper	IF	Citations
412	AACR Cancer Progress Report 2012. **2012**, 18, S1-100		20
411	HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. **2012**, 116, 131-63		29
410	Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells. **2012**, 51, 6880-8		19
409	Drug Allergy. **2013**,		26
408	Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. **2013**, 97, 800-3		20
407	Current approaches for the treatment of multiple myeloma. **2013**, 97, 333-44		23
406	Georgia on my mind: multiple myeloma highlights at ASH 2012. **2013**, 6, 189-192		0
405	Topical evening primrose oil for reduction of bortezomib-induced skin reactions. **2013**, 92, 995-6		1
404	Subcutaneous bortezomib: in multiple myeloma. **2013**, 73, 45-54		14
403	Proteasome inhibitor therapy for Waldenstrm's macroglobulinemia. **2013**, 13, 235-7		4
402	Macrophages in multiple myeloma: emerging concepts and therapeutic implications. **2013**, 54, 2112-21		38
401	High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. **2013**, 98, 694-701		4
400	Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. **2013**, 10, 120		22
399	Why proteasome inhibitors cannot ERADicate multiple myeloma. **2013**, 24, 275-7		28
398	Current & Emerging Therapeutics for Multiple Myeloma. **2013**,		
397	To Market, To Market 2012. **2013**, 48, 471-546		10
396	Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. **2013**, 54, 1996-2002		24

395	SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. **2013**, 15, 72-81	60
394	Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. **2013**, 40, 634-51	34
393	Initial treatment of transplant candidates with multiple myeloma. **2013**, 40, 585-91	7
392	Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. **2013**, 41, 1038-49	21
391	Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. **2013**, 90, 157-61	14
390	Profiling drug-induced cell death pathways in the zebrafish lateral line. **2013**, 18, 393-408	48
389	Proteasome inhibitors in acute leukemia. **2013**, 13, 327-37	35
388	Proteasome inhibitor MG-132 induces MCPIP1 expression. **2013**, 280, 2665-74	24
387	Emerging pathways as individualized therapeutic target of multiple myeloma. **2013**, 13 Suppl 1, S95-109	34
386	Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. **2013**, 2, 2	16
385	Understanding, recognizing, and managing toxicities of targeted anticancer therapies. **2013**, 63, 249-79	222
384	Takeda's Oncology Discovery Strategy. **2013**, 43, 357-61	2
383	Drugs Used for Chemotherapy. **2013**, 399-418	1
382	Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. **2013**, 12, 747-58	61
381	Degradation of NF-B, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. **2013**, 34, 990-1000	23
380	The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. **2013**, 288, 25593-25602	20
379	Panobinostat in lymphoid and myeloid malignancies. **2013**, 22, 1211-23	34
378	Second autologous transplant as salvage therapy in multiple myeloma. **2013**, 163, 565-72	29

377	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood*, **2013**, 121, 5055-63	2.2	153
376	Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. **2013**, 42, 1541-50		73
375	Bortezomib for the treatment of multiple myeloma. **2013**,		3
374	Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. **2013**, 98, 1896-904		46
373	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. **2013**,		
372	Non-covalent proteasome inhibitors. **2013**, 19, 4115-30		14
371	Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. **2013**, 8, e60649		10
370	Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma. **2013**, 8, e64369		7
369	Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. **2013**, 8, e73710		38
368	1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome. **2013**, 20, 2351-62		23
367	Proteasomes and Proteasomal Gene Polymorphism in Association with Inflammation and Various Diseases. **2013**, 49, 33		1
366	Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. **2014**, 9, e109018		20
365	Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. **2014**, 5, 720-7		18
364	Recent Developments in Cancer Treatment: A Review. **2014**, 03,		
363	Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma. **2014**, 6, CMT.S9308		1
362	Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. **2014**, 10, 1795-807		69
361	The emerging role of carfilzomib combination therapy in the management of multiple myeloma. **2014**, 7, 265-90		19
360	Immunotherapeutic approaches to treat multiple myeloma. **2014**, 10, 896-910		7

359	Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. **2014**, 4, e212		6
358	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood*, **2014**, 124, 1038-46	2.2	171
357	Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series. **2014**, 7, 977-981		3
356	The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients. **2014**, 2014, 237698		1
355	Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient. **2014**, 2014, 510408		2
354	Expression profile of the Schistosoma japonicum degradome reveals differential protease expression patterns and potential anti-schistosomal intervention targets. **2014**, 10, e1003856		20
353	Quantitative analysis of a ubiquitin-dependent substrate using capillary electrophoresis with dual laser-induced fluorescence. **2014**, 35, 2978-85		
352	Calcineurin inhibitors suppress the high-temperature stress sensitivity of the yeast ubiquitin ligase Rsp5 mutant: a new method of screening for calcineurin inhibitors. **2014**, 14, 567-74		8
351	Profiling Bortezomib Resistance in Multiple Myeloma: Implications in Personalized Pharmacotherapy. **2014**, 117-147		1
350	Molecular pathways: translational potential of deubiquitinases as drug targets. **2014**, 20, 3908-14		45
349	Profile of elotuzumab and its potential in the treatment of multiple myeloma. **2014**, 2014, 15-27		22
348	The complexity of recognition of ubiquitinated substrates by the 26S proteasome. **2014**, 1843, 86-96		109
347	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group. **2014**, 38, 788-94		3
346	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. **2014**, 61, 39-43		10
345	Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. **2014**, 33, 1877-89		22
344	Total synthesis of syringolin A and improvement of its biological activity. **2014**, 53, 4836-9		16
343	Peptide-based proteasome inhibitors in anticancer drug design. **2014**, 34, 1001-69		40
342	Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. **2014**, 135, 2950-61		38

341	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. **2014**, 28, 993-1000	81
340	Mechanisms and consequences of constitutive NF-Β activation in B-cell lymphoid malignancies. **2014**, 33, 5655-65	82
339	Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. **2014**, 20, 1899-904	20
338	Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model. **2014**, 134, 218-23	11
337	An iron-regulated and glycosylation-dependent proteasomal degradation pathway for the plasma membrane metal transporter ZIP14. **2014**, 111, 9175-80	43
336	Degradation of a connexin40 mutant linked to atrial fibrillation is accelerated. **2014**, 74, 330-9	18
335	Resistance to Proteasome Inhibitors in Cancer. **2014**,	2
334	Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses. **2014**, 34, 565-96, viii	24
333	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. **2014**, 28, 1216-26	45
332	European perspective on multiple myeloma treatment strategies in 2014. **2014**, 19, 829-44	77
331	Initial treatment of transplant-eligible patients in multiple myeloma. **2014**, 7, 43-53	12
330	A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. **2014**, 15, 231	18
329	Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. **2014**, 21, 2322-43	41
328	MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-Β. **2014**, 395, 253-63	12
327	Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. **2014**, 73, 1263-71	9
326	Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells. **2014**, 42, 172-82	18
325	An analysis of the safety profile of proteasome inhibitors for treating various cancers. **2014**, 13, 1043-54	11
324	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. **2014**, 99, 726-36	11

323	HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. **2014**, 1842, 613-22		39
322	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. **2014**, 92, 61-70		16
321	Development of inhibitors in the ubiquitination cascade. **2014**, 588, 356-67		57
320	Neurotoxicity induced by antineoplastic proteasome inhibitors. **2014**, 43, 28-35		38
319	Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth. **2014**, 1840, 2004-13		20
318	Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. **2014**, 14, 380-8		34
317	The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. **2014**, 1843, 150-62		165
316	DNA damage emergency: cellular garbage disposal to the rescue?. **2014**, 33, 805-13		15
315	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. **2014**, 99, 951-3		
314	Treatment of chronic graft-versus-host disease with bortezomib. *Blood*, **2014**, 124, 1677-88	2.2	60
313	First do no harm: infectious deaths in pediatric ALL. *Blood*, **2014**, 124, 987-9	2.2	
312	Oral therapy for multiple myeloma: ixazomib arriving soon. *Blood*, **2014**, 124, 986-7	2.2	14
311	Total Synthesis of Syringolin A and Improvement of Its Biological Activity. **2014**, 126, 4936-4939		4
310	Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment. **2015**, 6, e1934		30
309	How I treat fragile myeloma patients. *Blood*, **2015**, 126, 2179-85	2.2	57
308	Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. **2015**, 2, e000121		7
307	Dziesi□ciolecie Polskiej Grupy Szpiczakowej □historia i osi□gni□cia. **2015**, 46, 212-223		
306	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. **2015**, 21, 2730-6		29

305	Emerging therapies in multiple myeloma. **2015**, 38, 315-21	21
304	KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. **2015**, 10, e0144825	11
303	Heat Shock Protein 90 and the Proteasome. **2015**, 779-788.e3	0
302	Regulation of c-Myc protein stability by proteasome activator REG **2015**, 22, 1000-11	31
301	When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. **2015**, 13, 1163-73	34
300	Well plate-based perfusion culture device for tissue and tumor microenvironment replication. **2015**, 15, 2854-2863	9
299	An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma. **2015**, 133, 29-30	0
298	Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. **2015**, 33, 782-5	13
297	Clinical use of proteasome inhibitors in the treatment of multiple myeloma. **2014**, 8, 1-20	53
296	Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core. **2015**, 6, 7573	35
295	Inhibition of the 26S proteasome by peptide mimics of the coiled-coil region of its ATPase subunits. **2015**, 468, 143-50	7
294	Relevance of the thyroid hormones- 3 pathway in primary myeloma bone marrow cells and to bortezomib action. **2015**, 56, 1107-14	21
293	Treatment-related symptom management in patients with multiple myeloma: a review. **2015**, 23, 1431-45	27
292	The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. **2015**, 74, 1474-8	214
291	Trial Watch: Proteasomal inhibitors for anticancer therapy. **2015**, 2, e974463	15
290	Other Nonbiological Approaches to Targeted Cancer Chemotherapy. **2015**, 493-560	1
289	Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma. **2015**, 8, 481-91	24
288	Onconephrology. **2015**,	

287	PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. **2015**, 99, 202-16	30
286	Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. **2015**, 79, 789-800	44
285	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. **2015**, 211, 44-52	40
284	Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. **2015**, 43, 168-176.e2	9
283	Mixed galactolipid anomers accentuate apoptosis of multiple myeloma cells by inducing DNA damage. **2015**, 408, 114-8	6
282	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. **2015**, 33, 652-63	32
281	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. **2015**, 17, 17	66
280	Proteasome inhibitors. **2015**, 96, 1-9	115
279	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. **2015**, 21, 2660-2	36
278	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. **2015**, 11, 1153-68	23
277	Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. **2015**, 169, 423-34	72
276	The novel □2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. **2015**, 76, 383-96	11
275	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. **2015**, 6, 8428	39
274	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. **2015**, 100, 964-9	49
273	Regulation of Proteasomal Degradation by Modulating Proteasomal Initiation Regions. **2015**, 10, 2537-43	13
272	The Amyloidoses. **2015**, 279-307	
271	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. **2015**, 5, e338	62
270	Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. **2015**, 33, 732-9	80

269	Current treatment landscape for relapsed and/or refractory multiple myeloma. **2015**, 12, 42-54		146
268	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. **2015**, 168, 14-25		27
267	A review of the evidence for occupational exposure risks to novel anticancer agents - A focus on monoclonal antibodies. **2016**, 22, 121-34		15
266	Congenital Immunodeficiency Diseases. **2016**, 45-81		
265	Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. **2016**, 7, 77543-77557		46
264	Zoledronic acid overcomes adriamycin resistance in acute myeloid leukemia cells by promoting apoptosis. **2016**, 14, 5660-5666		2
263	APEH Inhibition Affects Osteosarcoma Cell Viability via Downregulation of the Proteasome. **2016**, 17,		11
262	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. **2016**, 122, 2050-6		30
261	Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy. **2016**, 239, 262-73		22
260	The role of the proteasome in AML. **2016**, 6, e503		24
259	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. *Blood*, **2016**, 128, 2415-2422	2.2	42
258	Targeting CK2-driven non-oncogene addiction in B-cell tumors. **2016**, 35, 6045-6052		16
257	Noncanonical NF-ΒB Signaling in Health and Disease. **2016**, 22, 414-429		171
256	Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. **2016**, 251, 26-33		22
255	Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. **2016**, 6, e411		12
254	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. **2016**, 29, 639-652		67
253	Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. **2016**, 30, 2198-2207		76
252	Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. **2016**, 33, 53		16

251	Molecular mechanisms for vascular complications of targeted cancer therapies. **2016**, 130, 1763-79	13
250	Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. **2016**, 30, 2169-2178	26
249	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. **2016**, 9, 82	15
248	NF-B dysregulation in multiple myeloma. **2016**, 39, 68-76	32
247	Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. **2016**, 142, 2141-58	9
246	Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. **2016**, 11, 2273-2279	33
245	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. **2016**, 7, 345-355	11
244	Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. **2016**, 4, 779-88	66
243	Integration of Novel Agents into the Care of Patients with Multiple Myeloma. **2016**, 22, 5443-5452	26
242	Targeted inhibition of the COP9 signalosome for treatment of cancer. **2016**, 7, 13166	88
241	Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition. **2016**, 291, 26177-26187	17
240	Carfilzomib for treating myeloma. **2016**, 4, 989-999	2
239	Novel immunotherapeutic strategies to target alloantibody-producing B and plasma cells in transplantation. **2016**, 21, 419-26	9
238	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). **2016**, 101, 346-55	36
237	Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. **2016**, 16, 247	6
236	Leveraging protein quaternary structure to identify oncogenic driver mutations. **2016**, 17, 137	6
235	New MAPS for misfolded proteins. **2016**, 18, 724-6	5
234	Bortezomib for the treatment of multiple myeloma. **2016**, 4, CD010816	43

233	Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells. **2016**, 38, 87-97	11
232	Oral ixazomib maintenance therapy in multiple myeloma. **2016**, 16, 21-32	5
231	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. **2016**, 76, 3319-31	28
230	HIV-associated Hematological Malignancies. **2016**,	4
229	Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance. **2016**, 57, 1382-8	5
228	Impairment of stress granule assembly via inhibition of the eIF2alpha phosphorylation sensitizes glioma cells to chemotherapeutic agents. **2016**, 127, 253-60	32
227	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. **2016**, 30, 1094-102	42
226	Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. **2017**, 17, 40	48
225	Targeting proteasomes in infectious organisms to combat disease. **2017**, 284, 1503-1517	32
224	Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a. **2017**, 56, 98-108	12
223	Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. **2017**, 12, 257-267	2
222	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. **2017**, 292, 3543-3551	32
221	Discovery of an Inhibitor of the Proteasome Subunit Rpn11. **2017**, 60, 1343-1361	50
220	Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. **2017**, 77, 3293-3305	33
219	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. **2017**, 36, 4481-4497	13
218	MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. **2017**, 8, e2776	31
217	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. **2017**, 178, 547-560	38
216	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. **2017**, 7, e569	6

215	High-resolution cryo-EM proteasome structures in drug development. **2017**, 73, 522-533	8
214	A Mathematical Model of Cell Cycle Dysregulation Due to Human Papillomavirus Infection. **2017**, 79, 1564-1585	3
213	Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. **2017**, 178, 781-793	11
212	The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib. **2017**, 72, 391-398	12
211	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. **2017**, 92, 578-598	88
210	Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report. **2017**, 58, 2770-2771	0
209	Waldenstrm Macroglobulinemia: Review of Pathogenesis and Management. **2017**, 17, 252-262	25
208	Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. **2017**, 20, 267-272	9
207	CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma. **2017**, 16, 2862-2870	32
206	Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?. **2017**, 5, 875-887	1
205	Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. **2017**, 96, 1857-1866	12
204	The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. **2017**, 18, 584-595	19
203	The immunoproteasome: An old player with a novel and emerging role in alloimmunity. **2017**, 17, 3033-3039	27
202	ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. **2017**, 27, 4082-4085	16
201	The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target. **2017**, 3, 830-838	72
200	Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. **2017**, 102, 1861-1868	30
199	Small-Molecule Modulation of Protein Homeostasis. **2017**, 117, 11269-11301	147
198	Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. **2017**, 7, 650	14

197	An overview of the role of carfilzomib in the treatment of multiple myeloma. **2017**, 18, 1883-1897	18
196	Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sj□gren's syndrome. **2017**,	33
195	Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. **2017**, 10, 632-640	15
194	Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma. **2017**, 12, 535-542	13
193	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. **2017**, 7, e581	27
192	Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors. **2017**, 32, 865-877	7
191	Proteasomal Dysfunction Induced By Diclofenac Engenders Apoptosis Through Mitochondrial Pathway. **2017**, 118, 1014-1027	10
190	Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. **2017**, 58, 797-808	4
189	Second Generation Proteasome Inhibitors in Multiple Myeloma. **2017**, 17, 920-926	10
188	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. **2017**, 14, 3185-3192	4
187	Reduced response of IRE1β□Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells. **2017**, 103, 261-267	5
186	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. **2017**, 10,	29
185	Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors. **2017**, 9,	11
184	High Cut-Off Hemodialysis for Myeloma Cast Nephropathy □Do We Finally Have An Answer?. **2017**, 1, 67-70	5
183	Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. **2017**, 2017, 2861596	5
182	Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma. **2017**, 8, 839-851	13
181	Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. **2017**, 8, 1801-1808	4
180	Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. **2017**, 5, 7	69

179	Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. **2017**, 9, 307-314	10
178	Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum. **2018**, 78, 253-257	2
177	Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide. **2018** , 36, 797-809	5
176	Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome. **2018**, 74, 230-238	1
175	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. **2018**, 101, 220	12
174	Panobinostat and Multiple Myeloma in 2018. **2018**, 23, 516-517	32
173	PD-1 /PD-L1 checkpoint in hematological malignancies. **2018**, 67, 45-55	25
172	A rare yet emerging cause of bacterial meningitis. **2018**, 11, 61-63	3
171	Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma. **2018**, 4, 2	2
170	Natural scaffolds in anticancer therapy and precision medicine. **2018**, 36, 1563-1585	24
169	Frail Patients with Newly Diagnosed Multiple Myeloma. **2018**, 539-549	
168	The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma. **2018**, 67, 935-947	20
167	Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3. **2018**, 100, 486-494	21
166	Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. **2018**, 18, 311-320	25
165	Indomethacin elicits proteasomal dysfunctions develops apoptosis through mitochondrial abnormalities. **2018**, 233, 1685-1699	8
164	Personalized Therapy for Multiple Myeloma. **2018**,	1
163	New and emerging therapies for acute and chronic graft host disease. **2018**, 9, 21-46	54
162	Positioning of proteasome inhibitors in therapy of solid malignancies. **2018**, 81, 227-243	75

161	Treatment of Patients in First or Second Relapse. **2018**, 77-102	
160	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. **2018**, 100, 10-19	6
159	The Influence of Metabolism on Drug Response in Cancer. **2018**, 8, 500	100
158	Ixazomib for the treatment of multiple myeloma. **2018**, 19, 1949-1968	32
157	Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome. **2018**, 6, 392	4
156	Pharmacophore-based virtual screening for identifying □5 subunit inhibitor of 20S proteasome. **2018**, 77, 64-71	4
155	Proteasome-mediated protein degradation is enhanced by fusion ubiquitin with unstructured degron. **2018**, 501, 948-954	2
154	Profilin 1 induces drug resistance through Beclin1 complex-mediated autophagy in multiple myeloma. **2018**, 109, 2706-2716	20
153	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. **2018**, 8, 70	11
152	1,2,3,4,6-Penta--Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression. **2018**, 9, 65	6
151	Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. **2018**, 9, 365	38
150	Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). **2018**, 103, 1422-1432	44
149	Oncolytic Viruses for Multiple Myeloma Therapy. **2018**, 10,	16
148	A Complex Scenario and Underestimated Challenge: The Tumor Microenvironment, ER Stress, and Cancer Treatment. **2018**, 25, 2465-2502	17
147	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. **2018**, 11, 29	25
146	Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors. **2018**, 140, 11424-11437	31
145	Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones. **2018**, 41, 623-636	15
144	Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. **2019**, 58, 157-168	50

143	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. **2019**, 343, 219-297	7
142	Anti-Multiple Myeloma Potential of Secondary Metabolites from. **2019**, 24,	9
141	MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy. **2019**, 36, 75	4
140	Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors. **2019**, 27, 4151-4162	3
139	XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. **2019**, 209, 103504	21
138	DUBs, Hypoxia, and Cancer. **2019**, 5, 632-653	53
137	Loss of FBXO9 Enhances Proteasome Activity and Promotes Aggressiveness in Acute Myeloid Leukemia. **2019**, 11,	7
136	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. **2019**, 38, 3216-3231	23
135	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. **2019**, 33, 1736-1746	29
134	Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-□Subunit Abundance. **2019**, 8,	8
133	Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. **2019**, 234, 23785-23797	34
132	Synthesis and Biological Activity of Peptide □Ketoamide Derivatives as Proteasome Inhibitors. **2019**, 10, 1086-1092	10
131	An optical and non-invasive method to detect the accumulation of ubiquitin chains. **2019**, 43, 1393	1
130	Acute Renal Failure in Critically Ill Cancer Patients. **2019**, 1-16	
129	Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. **2019**, 207-228	1
128	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. **2019**, 33, 2266-2275	188
127	Renal Replacement Therapy in Critically Ill Cancer Patients. **2019**, 1-12	
126	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. **2019**, 17, 2331-2340	11

125	Proteostasis In The Endoplasmic Reticulum: Road to Cure. **2019**, 11,	15
124	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. **2019**, 2019,	5
123	Targeting Metalloenzymes for Therapeutic Intervention. **2019**, 119, 1323-1455	109
122	Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. **2019**, 26, 340-351.e3	44
121	Non-peptidic natural products as ubiquitin-proteasome inhibitors. **2019**, 75, 817-853	4
120	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. **2019**, 184, 536-546	12
119	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. **2019**, 11,	45
118	Quantitative structure-activity relationship and molecular docking studies on human proteasome inhibitors for anticancer activity targeting NF-Β signaling pathway. **2020**, 38, 3621-3632	1
117	Discovery of a Small Molecule Probe of Rpn-6, an Essential Subunit of the 26S Proteasome. **2020**, 15, 554-561	4
116	Tunable Synthesis of Α-Amino Boronic Esters from Available Aldehydes and Amines through Sequential One-Pot Dehydration and Copper-Catalyzed Borylacylation. **2020**, 85, 2716-2724	13
115	Renal replacement therapies. **2020**, 290-298.e3	
114	Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. **2020**, 26, 5506-5519	12
113	Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. **2020**, 39, 5888-5901	4
112	Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer. **2020**, 14, 4327-4342	8
111	Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. **2020**, 26, 5952-5961	3
110	Charge transfer reaction mechanisms of epoxyketone and boronated peptides at glassy carbon and boron doped diamond electrodes. **2020**, 878, 114733	0
109	Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. **2020**, 12, 8267	1
108	Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity. **2020**, 18, 1453-1464	8

107	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. **2020**, 18, 632-643		6
106	Proteasome Inhibitors for the Treatment of Multiple Myeloma. **2020**, 12,		56
105	Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients. **2020**, 12, 431-441		3
104	Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux. **2021**, 17, 961-979		12
103	Resistance mechanisms to immune checkpoints□blockade by monoclonal antibody drugs in cancer immunotherapy: Focus□on myeloma. **2021**, 236, 791-805		3
102	Light-Controlled Cell-Cycle Arrest and Apoptosis. **2021**, 60, 1187-1196		11
101	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. *Blood*, **2021**, 137, 1050-1060	2.2	4
100	Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance. **2021**, 124, 770-776		2
99	Light-Controlled Cell-Cycle Arrest and Apoptosis. **2021**, 133, 1207-1216		1
98	[The proteasome - structural aspects and inhibitors: a second life for a validated drug target]. **2021**, 215, 1-23		0
97	□Aminoboronates: recent advances in their preparation and synthetic applications. **2021**, 50, 12151-12188		3
96	MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase. **2021**, 14, 455-467		8
95	Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival.		
94	Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-□B Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. **2021**, 9,		4
93	The role of carfilzomib in relapsed/refractory multiple myeloma. **2021**, 12, 20406207211019612		2
92	Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy. **2021**, 12, 6198-6208		0
91	Multiple Myeloma. **2021**, 283-301		
90	Old and new generation proteasome inhibitors in multiple myeloma. **2020**, 62, 193-206		1

89	The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. **2021**, 13,	4
88	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. **2021**, 65, 103242	2
87	Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. **2021**, 118,	4
86	Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia. **2021**, 112, 2287-2298	2
85	Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. **2021**, 549, 1-7	3
84	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). **2021**, 56, 2533-2543	1
83	Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. **2021**, 22,	1
82	Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma. **2021**, 11, 4451	1
81	Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. **2021**, 81, 4581-4593	2
80	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. **2021**, 10781552211015283	0
79	Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma. **2021**, 13, e15943	1
78	Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome. **2021**, 9, e04287	0
77	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). **2021**, 21, e510-e520	2
76	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. **2021**, 13,	3
75	Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. **2021**, 398, 665-674	33
74	An update of new small-molecule anticancer drugs approved from 2015 to 2020. **2021**, 220, 113473	11
73	Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. **2021**, 520, 132-142	6
72	Targeted Drugs for Cancer Therapy: Small Molecules and Monoclonal Antibodies. **2021**, 595-644	2

71	Introduction. **2013**, 1-18	1
70	Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies. **2014**, 181-204	1
69	Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. **2020**, 111, 1279-1290	13
68	The dynamics of connexin expression, degradation and localisation are regulated by gonadotropins during the early stages of in vitro maturation of swine oocytes. **2013**, 8, e68456	27
67	Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. **2013**, 8, e77608	16
66	Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. **2014**, 9, e103015	22
65	Inhibition of apoptosis may lead to the development of bortezomib resistance in multiple myeloma cancer cells. **2021**, 46, 65-71	1
64	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. **2016**, 7, 59727-59741	18
63	Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. **2016**, 7, 70845-70856	26
62	CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. **2016**, 7, 78605-78618	5
61	Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. **2014**, 5, 7065-80	22
60	Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway. **2017**, 8, 114123-114135	11
59	□Radioimmunotherapy with □□□Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. **2015**, 6, 4692-703	38
58	KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. **2015**, 6, 14814-31	51
57	Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. **2014**, 14, 517-36	173
56	Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature. **2020**, 15, 113-131	6
55	Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma. **2020**, 16, 1125-1136	2
54	Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. **2019**, 19, 5023-5029	1

53	comparison of the cytotoxic effects of statins on U266 myeloma cell line. **2019**, 150, 630-634	3
52	Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses. **2015**, 6, 308-18	4
51	Nostocyclopeptides as New Inhibitors of 20S Proteasome. **2021**, 11,	0
50	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. **2021**, 10,	1
49	Targeted treatment of multiple myeloma: proteasome inhibitors. **2013**, 82-102	
48	Future directions. **2013**, 114-135	
47	AIDS-Related Plasmablastic Lymphoma. **2016**, 73-81	
46	Loss of FBXO9 enhances proteasome activity and promotes aggressiveness in acute myeloid leukemia.	
45	Renal Replacement Therapy in Critically Ill Cancer Patients. **2020**, 937-948	
44	A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma.	
43	Acute Renal Failure in Critically Ill Cancer Patients. **2020**, 921-936	
42	Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. **2013**, 4, 307-21	9
41	Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma. **2017**, 8, 401-405	
40	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. **2018**, 11, 304-313	7
39	[Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy]. **2020**, 41, 583-588	
38	Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by pan-proteasome inhibitors. **2021**,	0
37	MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.. **2022**, 114, 106785	1
36	Cancer-cell-biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing. **2021**, e2107883	5

35	Induction of mA methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance.. **2022**, 41, 4	4
34	poly(I:C) synergizes with proteasome inhibitors to induce apoptosis in cervical cancer cells.. **2022**, 18, 101362	0
33	Microbial proteasomes as drug targets. **2021**, 17, e1010058	3
32	Neurological complications of multiple myeloma. **2022**, 415-431	
31	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.. **2022**, 12, 39	1
30	Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome.. **2022**,	0
29	Production of Epoxyketone Peptide-Based Proteasome Inhibitors by sp. BRA-346: Regulation and Biosynthesis.. **2022**, 13, 786008	
28	3D bioprinted, vascularized neuroblastoma tumor environment in fluidic chip devices for precision medicine drug testing.. **2022**,	1
27	Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials.. **2021**,	3
26	Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. **2021**, e022247	1
25	A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.. **2022**,	0
24	Data_Sheet_1.DOCX. **2018**,	
23	Image_1.PDF. **2018**,	
22	Table_1.DOCX. **2018**,	
21	Multiple myeloma metabolism □a treasure trove of therapeutic targets?. 13,	1
20	The □in and Yang□of Unfolded Protein Response in Cancer and Immunogenic Cell Death. **2022**, 11, 2899	0
19	Therapeutic peptidomimetics for cancer treatment. **2022**, 473-505	0
18	Structural Aspects of Organic Compounds as Proteasome Inhibitors Addressed to Several Diseases. **2022**, 545-567	0

17	The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. **2022**, 13, 204062072211128	1
16	Plasma Cell Disorders. 1-30	0
15	Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. **2022**, 14, 5311	0
14	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. **2022** , 11, 3365	0
13	Rebooting the Myeloma Treatment Programme. 36-43	0
12	Patient Characteristics, Treatment Patterns and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. **2022**,	0
11	Systemic Metabolomic Changes Associated with Chemotherapy: Role in Personalized Therapy. **2022** , 811-839	0
10	Subcutaneous injection of a bortezomib-loaded thermosensitive hydrogel for the treatment of multiple myeloma. **2022**, 140600	0
9	HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. **2022**, 17, e0274704	0
8	Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma.	0
7	Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma. **2023**,	0
6	Patterns of the Expression of Cyclin Genes in Bortezomib-Sensitive and Resistant Cells of Multiple Myeloma. **2022**, 49, S37-S45	0
5	Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. **2023**, 13,	0
4	Comprehensive Structure–Activity Relationship Studies of Cepafungin Enabled by Biocatalytic C–H Oxidations.	1
3	Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma. **2023**, 28, 1438	1
2	Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. **2023**, 42, 994-1009	0
1	Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics. **2023**, 13, 509	0